NPC Archive Item: Another biologic for the treatment of psoriasis

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 25th February 2009 “Subcutaneous ustekinumab▼ (Stelara®) administered every twelve weeks was more effective than placebo for the treatment of moderate to severe psoriasis. This dosing frequency appears to maintain efficacy […]

NPC Archive Item: Incretin-based therapies in type 2 diabetes

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 24th February 2009 Madsbad S. Treatment of type 2 diabetes with incretin-based therapies. The Lancet 2009; 373:438-39 Incretin-based therapies may offer a new option in the treatment of type […]

NPC Archive Item: Oral telcagepant, a novel treatment for acute migraine

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 30th January 2009 Telcagepant 300mg improved relief of migraine pain and related symptoms two hours after a single dose as compared to placebo. The trial data suggests that the […]

NPC Archive Item: Publication bias identified for drugs receiving U.S licensing approval

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. North American authors of an observational study have found evidence of incomplete and selective publication of clinical trials that supported successful licence applications to the FDA during the time […]

NPC Archive Item: Liraglutide plus metformin data from the LEAD-2 Met trial

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). […]

NPC Archive Item: Early days for alemtuzumab▼ in early MS

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The CAMMS223 Trial Investigators. Alemtuzumab▼ vs. Interferon Beta-1a in Early Multiple Sclerosis. N Engl J Med 2008; 359:1786-801 Compared with interferon beta-1a, alemtuzumab▼ reduced the annualised risk of relapse and sustained […]